Join this live webinar led by our skin sensitization specialist Dr Andy Forreryd to learn the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and product development.
GARDskin approved by OECD
We are delighted to announce that SenzaGen’s GARDskin assay has been adopted by OECD as part of Test Guideline 442E for in vitro skin sensitization, which is a regulatory breakthrough for the GARD technology. As the first and only genomics and machine learning-based method, GARDskin has been approved for the third key event, dendritic cell activation. The scientific data published in the TG confirms the high performance and broad applicability of the method, bringing new opportunities to the field of in vitro skin sensitization testing.
The webinar will last around 30 minutes, followed by a live Q&A. If you cannot attend the live event, register now to get access to the recording.
Speakers
